Please provide your email address to receive an email when new articles are posted on . Nearly 10% of patients with systemic sclerosis had systemic sclerosis sine scleroderma, a subtype without skin ...

Although less common than other subtypes of systemic sclerosis (SSc), systemic sclerosis sine scleroderma (ssSSc) makes up more than 8% of SSc cases and "should not be neglected," according to a new ...

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...

Episodes of Raynaud's phenomenon, a common feature of systemic sclerosis (SSc, also known as scleroderma), were more severe not only at low temperatures, as one would expect, but also during ...

Opportunities lie in strategic investment formulation, identifying cost-effective locations for conducting trials, understanding global trial trends, and analyzing trial success rates. Insights into ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Clinicians managing systemic sclerosis should focus on treating “what is treatable” in each organ ...

Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.

The "Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com’s ...